A carregar...
Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
BACKGROUND: The effectiveness of atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer (TNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on advanced TNBC from the US payer perspective. METHODS: A Markov model was adopted to project the disease course of...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222249/ https://ncbi.nlm.nih.gov/pubmed/32426048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920916000 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|